/

NRIX

Nurix Therapeutics, Inc.Pre-market

22.16−0.19 −0.85%USD

NasdaqGM · as of Oct 12, 16:00 ET · 15m delayPre-market 22.60 +1.99%

Open

22.27

Prev close

22.35

Day range

22.0322.58

52-week range

9.1428.23

Volume

2.12M1.63×

Mkt cap

2.30B

P/E ttm

—

Fwd P/E

-20.80

EPS ttm

-3.49

Div yield

0.00%

Earnings

Oct 12, 2026

From 52w high

−21.50%

Price Chart

Yahoo Finance · delayed

NRIXOct 12, 2026O 22.27H 22.58L 22.02C 22.16−0.19 (−0.85%)Vol 2.85M

SMA 5025.16
SMA 20019.70

1Y change +127.05% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

NRIX Nurix Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −3.15%
1 month: −11.71%
3 months: −2.42%
6 months: +39.28%
Year to date: +16.82%
1 year: +127.05%

Valuation & ownership

Market cap: 2.30B
Enterprise value: 1.91B
P/E (ttm): —
Forward P/E: -20.80
PEG ratio: —
Price / book: 5.71
Price / sales (ttm): 62.55
EV / EBITDA: -5.42
EPS (ttm): -3.49
EPS (forward): -1.07
Beta (5y monthly): 1.82
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 103.78M
Float: 74.11M
Short % of float: 17.20%
Short ratio (days): 11.33
Held by insiders: 1.08%
Held by institutions: 114.88%
Avg volume (3m): 1.30M
50-day average: 25.16
200-day average: 19.70
52-week change: +127.05%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 31.0
vs 50-day SMA: −11.92%
vs 200-day SMA: +12.47%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.59%
Realised vol (20d, ann.): 33.4%
From 52-week high: −21.50%
From 52-week low: +146.22%

ANR

Analyst Consensus

14 analysts

Consensus

Strong buy

1.50 on a 1 (strong buy) – 5 (sell) scale

Mean target

34.14

+54.07% implied

Low 25.00Median 33.50High 45.00

Recommendation trend

Now12 / 1 / 0
1m ago / 1 /

DES

About Nurix Therapeutics, Inc.

Yahoo Finance profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 317
Headquarters: Brisbane, CA, United States
Website: nurixtx.com
Officers: Dr. Arthur T. Sands M.D., Ph.D. CEO, President & Director

SEAS

Seasonality · NRIX

2020–2026 · monthly returns

Strongest month Nov +14.98%Weakest month Mar −7.19%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-12.9	-3.3	-2.9	7.7	6.3	36.6	-4.3	11.1	-8.0	-6.5			+16.8%
2025	4.6	-21.6	-23.1	-2.9	-7.8	7.1	-1.1	-17.1	-1.1	40.0	36.6	7.3	+0.7%
2024	-23.4	56.3	19.0	-18.2	31.0	32.5	4.8	15.2	-10.8	9.4	-10.0	-14.8	+82.6%
2023	11.9	-23.3	-5.8	8.4	5.1	-1.3	-2.8	-12.5	-7.5	-28.9	11.3	65.9	−6.0%
2022	-35.7	-13.2	-13.4	-21.0	-8.9	25.6	26.0	-1.4	-17.2	-2.3	-2.7	-11.4	−62.1%
2021	10.6	-2.1	-12.7	12.0	-19.9	-4.9	15.9	4.7	-6.9	11.6	-13.8	0.5	−12.0%
2020								20.7	49.2	-27.6	68.5	-22.9	+69.6%

INSD

Insider Activity · NRIX

Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

117.1K shares

Sells, 6 months

137.5K shares

Net shares

−20.4K

Net change in insider shares

−1.80%

Date	Insider	Transaction	Shares	Value
Sep 1, 2026	Ring ChristineOfficer	Sale at price 25.69 - 26.64 per share.	5.8K	$149.07K
Sep 1, 2026	Ring ChristineOfficer	Conversion of Exercise of derivative security at price 8.72 per share.	5.8K	$50.46K
Aug 31, 2026	Hansen Gwenn MOfficer	Sale at price 25.47 per share.	1.5K	$36.98K
Aug 31, 2026	Hansen Gwenn MOfficer	Conversion of Exercise of derivative security at price 1.86 per share.	1.5K	$2.70K
Aug 4, 2026	Hansen Gwenn MOfficer	Sale at price 25.00 per share.	4.4K	$108.90K
Aug 4, 2026	Hansen Gwenn MOfficer	Conversion of Exercise of derivative security at price 1.86 per share.	4.4K	$8.10K
Aug 3, 2026	Van Houte Johannes DChief Financial Officer	Sale at price 23.89 - 24.65 per share.	4.8K	$115.99K
Aug 3, 2026	Hansen Gwenn MOfficer	Sale at price 23.87 - 24.64 per share.	4.1K	$100.14K
Aug 2, 2026	Ring ChristineOfficer	Sale at price 23.05 per share.	16.6K	$382.36K
Aug 2, 2026	Ring ChristineOfficer	Conversion of Exercise of derivative security at price 8.72 per share.	5.8K	$50.46K
Jul 29, 2026	Van Houte Johannes DChief Financial Officer	Sale at price 23.38 per share.	2.8K	$66.52K
Jul 29, 2026	Hansen Gwenn MOfficer	Sale at price 23.38 per share.	3.8K	$89.95K
Jul 29, 2026	Ring ChristineOfficer	Sale at price 23.38 per share.	3.8K	$89.95K
Jul 29, 2026	Ring ChristineOfficer	—	10.2K	—
Jul 29, 2026	Van Houte Johannes DChief Financial Officer	—	10.2K	—
Jul 29, 2026	Hansen Gwenn MOfficer	—	10.2K	—
Jul 1, 2026	Ring ChristineOfficer	Sale at price 23.56 per share.	11K	$259.37K
Jul 1, 2026	Ring ChristineOfficer	Conversion of Exercise of derivative security at price 1.86 - 8.72 per share.	11K	$60.17K
Jun 24, 2026	Hansen Gwenn MOfficer	Sale at price 20.00 per share.	5.4K	$107.88K
Jun 24, 2026	Ring ChristineOfficer	Sale at price 20.06 per share.	28.9K	$580.51K

NRIX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

NRIX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Nurix Therapeutics, Inc.

Seasonality · NRIX

Insider Activity · NRIX

Congress Trades · NRIX

Congress Trades · NRIX

Insider Activity · NRIX

Seasonality · NRIX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Nurix Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News